Suppr超能文献

母亲在妊娠早期使用苯二氮䓬类或 Z 类催眠药与死产、早产和小于胎龄儿风险的关联:一项在台湾的全国性基于人群的队列研究。

Association between maternal benzodiazepine or Z-hypnotic use in early pregnancy and the risk of stillbirth, preterm birth, and small for gestational age: a nationwide, population-based cohort study in Taiwan.

机构信息

Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.

Taiwan Drug Relief Foundation, Taipei, Taiwan.

出版信息

Lancet Psychiatry. 2023 Jul;10(7):499-508. doi: 10.1016/S2215-0366(23)00148-7.

Abstract

BACKGROUND

Benzodiazepines and Z-hypnotics are commonly prescribed for anxiety and insomnia during pregnancy, but the evidence regarding potential adverse neonatal outcomes is insufficient because of poor control for confounding factors in previous studies. We therefore aimed to evaluate the association between the use of benzodiazepines or Z-hypnotics during early pregnancy and adverse neonatal outcomes (stillbirth, preterm birth, and small for gestational age).

METHODS

We did a nationwide, population-based cohort study in Taiwan using three data sources: Taiwan's National Birth Certificate Application database, the National Health Insurance database, and the Maternal and Child Health Database. The study cohort included all singleton pregnancies of females aged 15-50 years who gave birth between Jan 1, 2004, and Dec 31, 2018. Pregnancies without valid information were excluded. Benzodiazepine and Z-hypnotic use was defined as at least one benzodiazepine or Z-hypnotic prescription during early pregnancy (the first 20 weeks of pregnancy). The primary outcomes were stillbirth (fetal death at or after 20 weeks' gestation), preterm birth (<37 weeks' gestation), and small for gestational age (birthweight below the 10th percentile for gestational age by sex). Logistic regression models with propensity score fine stratification weighting were used to control for potential confounders and examine the association between benzodiazepines or Z-hypnotics use during early pregnancy and the risk of adverse neonatal outcomes. Odds ratios (ORs) and 95% CIs were reported. We used confounding by indication control analyses, a sibling control study, and a paternal negative control design to account for unmeasured confounders. The risk associated with exposure during late pregnancy was also assessed.

FINDINGS

Between Oct 7, 2021, and June 10, 2022, we analysed the study data. The cohort included 2 882 292 singleton pregnancies; of which, 75 655 (2·6%) of the mothers were dispensed one or more benzodiazepines or Z-hypnotics during early pregnancy. Women exposed during pregnancy were older (mean age at delivery was 31·0 years [SD 5·3] for exposed women vs 30·6 years [4·9] for unexposed women), had a higher prevalence of psychiatric disorders, and were more likely to have unhealthy lifestyle behaviours than unexposed women. Information about ethnicity was not available. Early pregnancy exposure was associated with adverse neonatal outcomes compared with non-exposure. The propensity score-weighted OR was 1·19 (95% CI 1·10-1·28) for stillbirth, 1·19 (1·16-1·23) for preterm birth, and 1·16 (1·13-1·19) for small for gestational age. After controlling for confounding by indication, there was no significant association between drug exposure and stillbirth risk; however, this attenuation was not observed for preterm birth and small for gestational age. In models with sibling controls that accounted for familial confounding and genetic factors, early exposure to benzodiazepines or Z-hypnotics was not associated with an increased risk of stillbirth and preterm birth, but it remained significantly associated with small for gestational age. The paternal negative control analyses with point estimates close to the null indicated no strong evidence of unmeasured confounding shared by the mother and the father. Substantially increased risks of stillbirth and preterm birth were observed for late pregnancy exposure.

INTERPRETATION

Benzodiazepine or Z-hypnotic use in early pregnancy is not associated with a substantial increase in the risk of stillbirth and preterm birth after accounting for unmeasured confounding factors. Clinicians should be aware of the increased risk of small for gestational age and caution should be taken when prescribing these medications during late pregnancy.

FUNDING

National Science and Technology Council, Taiwan.

TRANSLATION

For the Taiwanese translation of the abstract see Supplementary Materials section.

摘要

背景

苯二氮䓬类药物和 Z 类催眠药常用于治疗妊娠期间的焦虑和失眠,但由于以前的研究中对混杂因素的控制不佳,关于其对新生儿潜在不良结局的证据不足。因此,我们旨在评估孕早期使用苯二氮䓬类药物或 Z 类催眠药与不良新生儿结局(死胎、早产和小于胎龄儿)之间的关系。

方法

我们在台湾进行了一项全国性、基于人群的队列研究,使用了三个数据源:台湾国家出生证明申请数据库、全民健康保险数据库和母婴健康数据库。研究队列包括 2004 年 1 月 1 日至 2018 年 12 月 31 日期间年龄在 15-50 岁之间的女性所生的所有单胎妊娠。没有有效信息的妊娠被排除在外。苯二氮䓬类药物和 Z 类催眠药的使用定义为至少使用一种苯二氮䓬类药物或 Z 类催眠药进行早期妊娠(妊娠的前 20 周)。主要结局是死胎(妊娠 20 周后或以上的胎儿死亡)、早产(<37 周)和小于胎龄儿(按性别出生体重低于胎龄第 10 百分位)。使用倾向评分精细分层加权的 logistic 回归模型来控制潜在混杂因素,并检查孕早期使用苯二氮䓬类药物或 Z 类催眠药与不良新生儿结局风险之间的关系。报告了比值比(OR)和 95%置信区间(CI)。我们使用混杂因素指示控制分析、同胞对照研究和父系负对照设计来考虑未测量的混杂因素。还评估了妊娠晚期暴露的风险。

结果

在 2021 年 10 月 7 日至 2022 年 6 月 10 日期间,我们分析了研究数据。队列包括 2882292 例单胎妊娠;其中,75655 名(2.6%)母亲在孕早期使用了一种或多种苯二氮䓬类药物或 Z 类催眠药。怀孕期间暴露的女性年龄较大(分娩时的平均年龄为 31.0 岁[标准差 5.3]),精神疾病患病率较高,且比未暴露的女性更有可能存在不健康的生活方式行为。种族信息不可用。与未暴露组相比,早期暴露与不良新生儿结局相关。经倾向评分加权后的 OR 为 1.19(95%CI 1.10-1.28)的死胎、1.19(1.16-1.23)的早产和 1.16(1.13-1.19)的小于胎龄儿。在控制混杂因素指示后,药物暴露与死胎风险之间没有显著关联;然而,这种减弱在早产和小于胎龄儿中没有观察到。在考虑了家族性混杂因素和遗传因素的同胞对照模型中,孕早期暴露于苯二氮䓬类药物或 Z 类催眠药与死产和早产风险的增加无关,但与小于胎龄儿仍显著相关。点估计接近零的父系负对照分析表明,母亲和父亲之间没有强烈的证据表明存在未测量的混杂因素。在妊娠晚期暴露的情况下,死产和早产的风险显著增加。

解释

在考虑了未测量的混杂因素后,孕早期使用苯二氮䓬类药物或 Z 类催眠药与死产和早产风险的增加无关。临床医生应注意到小于胎龄儿的风险增加,并在妊娠晚期谨慎使用这些药物。

资助

台湾国家科学技术委员会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验